Biggest News Aggregation in the World

📰 Lung Fact News

Lung Fact News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Lung Fact. Real-time updates on events, politics, business and more.

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

June 2, 2024

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 2, 2024--

United States United Kingdom Chelsea Tressler Daiichi Sankyo Brendan Mcevoy American Society Of Clinical Oncology

Source: joplinglobe.com

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

April 5, 2024

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial ...

United States United Kingdom Noord Holland Suresh Senan Susan Galbraith Daiichi Sankyo

Source: marketscreener.com

AstraZeneca : Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial - Form 6-K -April 05, 2024 at 06:26 am EDT

April 5, 2024

A4121j FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

United Kingdom United States Noord Holland Susan Galbraith Astrazeneca Imfinzi Adrian Kemp

Source: marketscreener.com

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

February 19, 2024

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting ...

United States United Kingdom Suresh Ramalingam Susan Galbraith Cerner Cancermpact Daiichi Sankyo

Source: marketscreener.com

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

October 23, 2023

TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--

United States Susan Galbraith Aaron Lisberg Daiichi Sankyo Jennifer Brennan Datopotamab Deruxtecan

Source: valdostadailytimes.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

October 23, 2023

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors Datopotamab...

United States United Kingdom Susan Galbraith Aaron Lisberg Daiichi Sankyo Ken Takeshita

Source: marketscreener.com

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

October 16, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 16, 2023--

United Kingdom United States Susan Galbraith Brendan Mcevoy Daiichi Sankyo Chelsea Ford

Source: eagletribune.com

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

September 11, 2023

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...

United Kingdom United States Daiichi Sankyo Single Institution Study Lung Ambition Alliance Company On Social Media Astrazeneca

Source: marketscreener.com

Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial

September 10, 2023

An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients BLA submission in U.S. planned for the second half of fiscal year 2023 ...

United States Helena Yu Ken Takeshita Daiichi Sankyo Patritumab Deruxtecan International Agency For Research On Cancer

Source: marketscreener.com

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

July 3, 2023

TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)--Jul 3, 2023--

United States Jennifer Brennan Susan Galbraith Ken Takeshita Ann Onc Koji Ogiwara

Source: valdostadailytimes.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science